NCT00669370View on ClinicalTrials.gov

Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

March 31, 2009

Conditions
Stomach Neoplasms
Interventions
DRUG

docetaxel and capecitabine

biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days

Trial Locations (6)

20521

RECRUITING

Department of Oncology and Radiotherapy, turku University Hospital, Turku

22850

NOT_YET_RECRUITING

Satakunta District Hospital, Pori

33520

RECRUITING

University of Tampere, Tampere

65100

RECRUITING

Vaasa Distric Hospital, Vaasa

70211

RECRUITING

Kuopio University Hospital, Kuopio

90029

RECRUITING

Oulu Univerity Hospital, Oulu

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

University of Turku

OTHER

NCT00669370 - Biweekly Docetaxel in Combination With Capecitabine as First-Line Treatment in Patients With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter